JP2019536812A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019536812A5 JP2019536812A5 JP2019531166A JP2019531166A JP2019536812A5 JP 2019536812 A5 JP2019536812 A5 JP 2019536812A5 JP 2019531166 A JP2019531166 A JP 2019531166A JP 2019531166 A JP2019531166 A JP 2019531166A JP 2019536812 A5 JP2019536812 A5 JP 2019536812A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- pharmaceutical composition
- acceptable salt
- olodaterol
- nintedanib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 239000000048 adrenergic agonist Substances 0.000 claims 7
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 7
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 claims 7
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 229960004378 nintedanib Drugs 0.000 claims 7
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 claims 7
- COUYJEVMBVSIHV-SFHVURJKSA-N olodaterol Chemical compound C1=CC(OC)=CC=C1CC(C)(C)NC[C@H](O)C1=CC(O)=CC2=C1OCC(=O)N2 COUYJEVMBVSIHV-SFHVURJKSA-N 0.000 claims 7
- 229960004286 olodaterol Drugs 0.000 claims 7
- 239000000243 solution Substances 0.000 claims 6
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 6
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 6
- 239000000443 aerosol Substances 0.000 claims 5
- 239000000725 suspension Substances 0.000 claims 5
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 4
- 239000000843 powder Substances 0.000 claims 4
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16203359.1 | 2016-12-12 | ||
| EP16203359 | 2016-12-12 | ||
| PCT/EP2017/081691 WO2018108669A1 (en) | 2016-12-12 | 2017-12-06 | Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019536812A JP2019536812A (ja) | 2019-12-19 |
| JP2019536812A5 true JP2019536812A5 (enExample) | 2021-01-21 |
Family
ID=57544282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531166A Ceased JP2019536812A (ja) | 2016-12-12 | 2017-12-06 | オロダテロールとの同時投与による間質性肺疾患の処置方法に使用するためのニンテダニブ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20200069679A1 (enExample) |
| EP (1) | EP3551187B1 (enExample) |
| JP (1) | JP2019536812A (enExample) |
| CN (1) | CN110062625A (enExample) |
| WO (1) | WO2018108669A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3280124A1 (en) | 2013-07-31 | 2025-10-31 | Avalyn Pharma Inc. | Aerosol imatinib compounds and uses thereof |
| CU24684B1 (es) | 2018-03-07 | 2023-10-06 | Pliant Therapeutics Inc | Compuestos de aminoácidos como inhibidores de la integrina |
| EP3841090A4 (en) * | 2018-08-22 | 2022-10-19 | Avalyn Pharma Inc. | SPECIALLY FORMULATED COMPOSITIONS OF INHALED NINTEDANIB AND NINTEDANIB SALTS |
| CA3197627A1 (en) * | 2020-11-18 | 2022-05-27 | Kimberly SHEPARD | Inhalable dry powder formulations comprising angiogenesis inhibitors |
| CN114617860A (zh) * | 2020-12-14 | 2022-06-14 | 南京华威医药科技集团有限公司 | 一种含尼达尼布的吸入液及其制备方法 |
| CN114642656B8 (zh) * | 2020-12-18 | 2025-12-12 | 盈科瑞（天津）创新医药研究有限公司 | 一种吸入用尼达尼布溶液及其制备方法 |
| US11331322B1 (en) | 2021-09-15 | 2022-05-17 | Santen Pharmaceutical Co., Ltd. | Medicament for preventing and/or treating dry eye |
| CN114869866B (zh) * | 2022-05-05 | 2024-02-20 | 珠海瑞思普利医药科技有限公司 | 一种治疗特发性肺纤维化的干粉吸入剂及其制备方法 |
| JP2025523707A (ja) * | 2022-05-28 | 2025-07-23 | アヴァリン ファーマ インク． | ニンテダニブおよびニンテダニブの組み合わせ乾燥粉末組成物と使用 |
| CN119857088A (zh) * | 2025-01-22 | 2025-04-22 | 杭州畅溪制药有限公司 | 复方吸入粉雾剂及其制备方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4460581A (en) * | 1982-10-12 | 1984-07-17 | Boehringer Ingelheim Kg | (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones |
| UA75054C2 (uk) | 1999-10-13 | 2006-03-15 | Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг | Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу |
| DE10233500A1 (de) | 2002-07-24 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel |
| DE10253282A1 (de) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung |
| DE102004019539A1 (de) | 2004-04-22 | 2005-11-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittel zur Behandlung von Atemwegserkrankungen |
| DE102004024454A1 (de) | 2004-05-14 | 2005-12-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004024452A1 (de) | 2004-05-14 | 2005-12-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Aerosolformulierung für die Inhalation von Betaagonisten |
| DE102004024451A1 (de) | 2004-05-14 | 2005-12-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten |
| PE20060777A1 (es) * | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| EP1917253B1 (de) | 2005-08-15 | 2015-01-07 | Boehringer Ingelheim International Gmbh | Verfahren zur herstellung von betamimetika |
| TWI389692B (zh) | 2005-10-10 | 2013-03-21 | Boehringer Ingelheim Int | 用以吸入β-共效劑的氣溶膠調配物 |
| US20070086957A1 (en) * | 2005-10-10 | 2007-04-19 | Thierry Bouyssou | Combination of medicaments for the treatment of respiratory diseases |
| EP1870400A1 (en) | 2006-06-08 | 2007-12-26 | Boehringer Ingelheim Pharma GmbH & Co. KG | Salts and crystalline salt forms of an 2-indolinone derivative |
| BRPI0807806A2 (pt) | 2007-01-25 | 2014-06-17 | Boehringer Ingelheim Int | " processo para a fabricação de beta-miméticos ". |
| UA107560C2 (uk) | 2008-06-06 | 2015-01-26 | Фармацевтична лікарська форма для негайного вивільнення похідної індолінону | |
| PL2299987T3 (pl) | 2008-06-06 | 2018-08-31 | Boehringer Ingelheim International Gmbh | Farmaceutyczna postać dawkowania w formie kapsułki zawierająca formulację zwiesiny pochodnej indolinonu |
| US20110319402A1 (en) | 2008-11-21 | 2011-12-29 | Boehringer Ingelheim International Gmbh | Aerosol formulation for the inhalation of beta agonists |
| JP2012509299A (ja) | 2008-11-21 | 2012-04-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | β作用薬吸入用のエアロゾル製剤 |
| WO2014056840A1 (en) * | 2012-10-09 | 2014-04-17 | Boehringer Ingelheim International Gmbh | Beta-2-adrenoceptor agonist for the treatment of cough |
-
2017
- 2017-12-06 CN CN201780076503.9A patent/CN110062625A/zh active Pending
- 2017-12-06 US US16/466,116 patent/US20200069679A1/en not_active Abandoned
- 2017-12-06 WO PCT/EP2017/081691 patent/WO2018108669A1/en not_active Ceased
- 2017-12-06 EP EP17811550.7A patent/EP3551187B1/en not_active Not-in-force
- 2017-12-06 JP JP2019531166A patent/JP2019536812A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017528507A5 (enExample) | ||
| JP2007533686A5 (enExample) | ||
| ZA200600411B (en) | Methods of treating COPD and Pulmonary Hypertension | |
| CN116712552A (zh) | 用于治疗疱疹病毒诱导的病况的方法和组合物 | |
| JP2009541443A5 (enExample) | ||
| RU2018136580A (ru) | Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты | |
| JP2006516570A5 (enExample) | ||
| JP2014526501A5 (enExample) | ||
| NZ597241A (en) | Pharmaceutical dosage form for oral administration of a bcl-2 family inhibitor | |
| HRP20251042T1 (hr) | Nova kombinacija aktivnih sredstava za liječenje progresivnih intersticijskih bolesti pluća s fibroznim promjenama (pf-ild) | |
| JP2017524663A (ja) | 線維性疾患の治療に用いられるｐｐａｒ化合物 | |
| JP2020523335A5 (enExample) | ||
| JP2014516942A5 (enExample) | ||
| JP2019515909A5 (enExample) | ||
| JP2020529995A5 (enExample) | ||
| JP2016530238A5 (enExample) | ||
| HRP20251043T1 (hr) | Novi oralni farmaceutski pripravak i režim doziranja za terapiju progresivnih fibrozirajućih intersticijskih bolesti pluća | |
| US20150104511A1 (en) | Pharmaceutical Antiretroviral Combinations Comprising Lamivudine, Festinavir and Nevirapine | |
| JP2021504384A5 (enExample) | ||
| JP2009532438A5 (enExample) | ||
| RU2011140239A (ru) | Фармацевтическая композиция, содержащая стероидное производное (3,2-с)пиразола и второе фармацевтически активное соединение | |
| EP4442321A3 (en) | Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor | |
| JP5362151B2 (ja) | Ｐｇｄ２拮抗剤及びヒスタミン拮抗剤からなるアレルギー性鼻炎治療用医薬 | |
| JP2004521856A (ja) | Ｃｏｘ−２選択的阻害剤およびトロンボキサン阻害剤を用いる併用療法ならびにそのための組成物 | |
| CR20210043A (es) | Forma de dosificación farmacèutica administrable por vía oral con liberación modificada |